Efficacy of live attenuated influenza vaccine against influenza illness in children as a function of illness severity
Abstract A recent study of inactivated influenza vaccine (IIV) in children aged 3–8 years demonstrated higher efficacy against moderate/severe influenza. A meta-analysis of all previous published randomized clinical trials of live attenuated influenza vaccine (LAIV) that collected information on ill...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2014-09, Vol.32 (43), p.5546-5548 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 5548 |
|---|---|
| container_issue | 43 |
| container_start_page | 5546 |
| container_title | Vaccine |
| container_volume | 32 |
| creator | Ambrose, Christopher S Wu, Xionghua Caspard, Herve Belshe, Robert B |
| description | Abstract A recent study of inactivated influenza vaccine (IIV) in children aged 3–8 years demonstrated higher efficacy against moderate/severe influenza. A meta-analysis of all previous published randomized clinical trials of live attenuated influenza vaccine (LAIV) that collected information on illness severity in children aged 24–71 months was conducted. Moderate/severe influenza was defined as fever >39 °C, acute otitis media, or lower respiratory tract illness; other cases were classified as milder influenza. LAIV efficacy versus placebo was 95.4% [95% confidence interval: 88.5, 98.1] (year 1) and 88.5% [77.4, 94.9] (year 2) against moderate/severe influenza and 91.4% [77.9, 96.7] (year 1) and 84.2% [56.7, 94.3] (year 2) against milder influenza. The relative efficacy of LAIV versus IIV was 52.2% [31.6, 66.6] for moderate/severe influenza and 45.0% [28.6, 57.5] for milder influenza. Efficacy against all influenza illnesses, regardless of severity, is critical to prevent influenza illness and transmission in the community. |
| doi_str_mv | 10.1016/j.vaccine.2014.07.097 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1622609962</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0264410X14010792</els_id><sourcerecordid>3471990361</sourcerecordid><originalsourceid>FETCH-LOGICAL-c628t-e12e14803525f5b65b0c8255b77b97e73b30900eb9616820d9db27ca114249663</originalsourceid><addsrcrecordid>eNqFkk1rFEEQhgdRTIz-BGVABC-7VvXnzMUgIX5AwIMK3pqenhrttbcnds8srL_eHnZjJJecGrqeeuvjrap6jrBGQPVms95Z53ykNQMUa9BraPWD6hQbzVdMYvOwOgWmxEogfD-pnuS8AQDJsX1cnZQ4Ry3UaTVfDoN31u3rcaiD31Ftp4nibCfqax-HMFP8Y-tjrdr-sD7m6b-IDyFSzuWndj996BPF2uba1sMc3eTHuAjfQJl2lPy0f1o9GmzI9Oz4nlXf3l9-vfi4uvr84dPFu6uVU6yZVoSMUDTAJZOD7JTswDVMyk7rrtWkecehBaCuVagaBn3bd0w7iyiYaJXiZ9Xrg-51Gn_PlCez9dlRCDbSOGeDijEFbavY_ahUgpe1MlHQl3fQzTinWAYpgqiE5AyX2vJAuTTmnGgw18lvbdobBLNYaDbmuFazWGhAm2JhyXtxVJ-7LfX_sm48K8CrI2Czs2FINjqfb7mm4Sj1InR-4KhseOcpmew8RUe9T-Qm04_-3lbe3lFwwcdyLuEX7SnfTm0yM2C-LPe2nBsKQNAt438BrcvQXQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1616453216</pqid></control><display><type>article</type><title>Efficacy of live attenuated influenza vaccine against influenza illness in children as a function of illness severity</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Ambrose, Christopher S ; Wu, Xionghua ; Caspard, Herve ; Belshe, Robert B</creator><creatorcontrib>Ambrose, Christopher S ; Wu, Xionghua ; Caspard, Herve ; Belshe, Robert B</creatorcontrib><description>Abstract A recent study of inactivated influenza vaccine (IIV) in children aged 3–8 years demonstrated higher efficacy against moderate/severe influenza. A meta-analysis of all previous published randomized clinical trials of live attenuated influenza vaccine (LAIV) that collected information on illness severity in children aged 24–71 months was conducted. Moderate/severe influenza was defined as fever >39 °C, acute otitis media, or lower respiratory tract illness; other cases were classified as milder influenza. LAIV efficacy versus placebo was 95.4% [95% confidence interval: 88.5, 98.1] (year 1) and 88.5% [77.4, 94.9] (year 2) against moderate/severe influenza and 91.4% [77.9, 96.7] (year 1) and 84.2% [56.7, 94.3] (year 2) against milder influenza. The relative efficacy of LAIV versus IIV was 52.2% [31.6, 66.6] for moderate/severe influenza and 45.0% [28.6, 57.5] for milder influenza. Efficacy against all influenza illnesses, regardless of severity, is critical to prevent influenza illness and transmission in the community.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2014.07.097</identifier><identifier>PMID: 25131746</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Kidlington: Elsevier Ltd</publisher><subject>Allergy and Immunology ; Applied microbiology ; Biological and medical sciences ; Child ; Child, Preschool ; Disease severity ; Fundamental and applied biological sciences. Psychology ; Humans ; Illnesses ; Influenza ; Influenza Vaccines - therapeutic use ; Influenza, Human - prevention & control ; Laboratories ; Live attenuated influenza vaccine ; Microbiology ; Randomized Controlled Trials as Topic ; Respiratory tract ; Severity of Illness Index ; Studies ; Vaccines ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) ; Vaccines, Attenuated - therapeutic use</subject><ispartof>Vaccine, 2014-09, Vol.32 (43), p.5546-5548</ispartof><rights>The Authors</rights><rights>2014 The Authors</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2014 The Authors. Published by Elsevier Ltd.. All rights reserved.</rights><rights>Copyright Elsevier Limited Sep 29, 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c628t-e12e14803525f5b65b0c8255b77b97e73b30900eb9616820d9db27ca114249663</citedby><cites>FETCH-LOGICAL-c628t-e12e14803525f5b65b0c8255b77b97e73b30900eb9616820d9db27ca114249663</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0264410X14010792$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28831577$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25131746$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ambrose, Christopher S</creatorcontrib><creatorcontrib>Wu, Xionghua</creatorcontrib><creatorcontrib>Caspard, Herve</creatorcontrib><creatorcontrib>Belshe, Robert B</creatorcontrib><title>Efficacy of live attenuated influenza vaccine against influenza illness in children as a function of illness severity</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Abstract A recent study of inactivated influenza vaccine (IIV) in children aged 3–8 years demonstrated higher efficacy against moderate/severe influenza. A meta-analysis of all previous published randomized clinical trials of live attenuated influenza vaccine (LAIV) that collected information on illness severity in children aged 24–71 months was conducted. Moderate/severe influenza was defined as fever >39 °C, acute otitis media, or lower respiratory tract illness; other cases were classified as milder influenza. LAIV efficacy versus placebo was 95.4% [95% confidence interval: 88.5, 98.1] (year 1) and 88.5% [77.4, 94.9] (year 2) against moderate/severe influenza and 91.4% [77.9, 96.7] (year 1) and 84.2% [56.7, 94.3] (year 2) against milder influenza. The relative efficacy of LAIV versus IIV was 52.2% [31.6, 66.6] for moderate/severe influenza and 45.0% [28.6, 57.5] for milder influenza. Efficacy against all influenza illnesses, regardless of severity, is critical to prevent influenza illness and transmission in the community.</description><subject>Allergy and Immunology</subject><subject>Applied microbiology</subject><subject>Biological and medical sciences</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Disease severity</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Humans</subject><subject>Illnesses</subject><subject>Influenza</subject><subject>Influenza Vaccines - therapeutic use</subject><subject>Influenza, Human - prevention & control</subject><subject>Laboratories</subject><subject>Live attenuated influenza vaccine</subject><subject>Microbiology</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Respiratory tract</subject><subject>Severity of Illness Index</subject><subject>Studies</subject><subject>Vaccines</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</subject><subject>Vaccines, Attenuated - therapeutic use</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkk1rFEEQhgdRTIz-BGVABC-7VvXnzMUgIX5AwIMK3pqenhrttbcnds8srL_eHnZjJJecGrqeeuvjrap6jrBGQPVms95Z53ykNQMUa9BraPWD6hQbzVdMYvOwOgWmxEogfD-pnuS8AQDJsX1cnZQ4Ry3UaTVfDoN31u3rcaiD31Ftp4nibCfqax-HMFP8Y-tjrdr-sD7m6b-IDyFSzuWndj996BPF2uba1sMc3eTHuAjfQJl2lPy0f1o9GmzI9Oz4nlXf3l9-vfi4uvr84dPFu6uVU6yZVoSMUDTAJZOD7JTswDVMyk7rrtWkecehBaCuVagaBn3bd0w7iyiYaJXiZ9Xrg-51Gn_PlCez9dlRCDbSOGeDijEFbavY_ahUgpe1MlHQl3fQzTinWAYpgqiE5AyX2vJAuTTmnGgw18lvbdobBLNYaDbmuFazWGhAm2JhyXtxVJ-7LfX_sm48K8CrI2Czs2FINjqfb7mm4Sj1InR-4KhseOcpmew8RUe9T-Qm04_-3lbe3lFwwcdyLuEX7SnfTm0yM2C-LPe2nBsKQNAt438BrcvQXQ</recordid><startdate>20140929</startdate><enddate>20140929</enddate><creator>Ambrose, Christopher S</creator><creator>Wu, Xionghua</creator><creator>Caspard, Herve</creator><creator>Belshe, Robert B</creator><general>Elsevier Ltd</general><general>Elsevier</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>7U2</scope></search><sort><creationdate>20140929</creationdate><title>Efficacy of live attenuated influenza vaccine against influenza illness in children as a function of illness severity</title><author>Ambrose, Christopher S ; Wu, Xionghua ; Caspard, Herve ; Belshe, Robert B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c628t-e12e14803525f5b65b0c8255b77b97e73b30900eb9616820d9db27ca114249663</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Allergy and Immunology</topic><topic>Applied microbiology</topic><topic>Biological and medical sciences</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Disease severity</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Humans</topic><topic>Illnesses</topic><topic>Influenza</topic><topic>Influenza Vaccines - therapeutic use</topic><topic>Influenza, Human - prevention & control</topic><topic>Laboratories</topic><topic>Live attenuated influenza vaccine</topic><topic>Microbiology</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Respiratory tract</topic><topic>Severity of Illness Index</topic><topic>Studies</topic><topic>Vaccines</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</topic><topic>Vaccines, Attenuated - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ambrose, Christopher S</creatorcontrib><creatorcontrib>Wu, Xionghua</creatorcontrib><creatorcontrib>Caspard, Herve</creatorcontrib><creatorcontrib>Belshe, Robert B</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>Safety Science and Risk</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ambrose, Christopher S</au><au>Wu, Xionghua</au><au>Caspard, Herve</au><au>Belshe, Robert B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of live attenuated influenza vaccine against influenza illness in children as a function of illness severity</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2014-09-29</date><risdate>2014</risdate><volume>32</volume><issue>43</issue><spage>5546</spage><epage>5548</epage><pages>5546-5548</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>Abstract A recent study of inactivated influenza vaccine (IIV) in children aged 3–8 years demonstrated higher efficacy against moderate/severe influenza. A meta-analysis of all previous published randomized clinical trials of live attenuated influenza vaccine (LAIV) that collected information on illness severity in children aged 24–71 months was conducted. Moderate/severe influenza was defined as fever >39 °C, acute otitis media, or lower respiratory tract illness; other cases were classified as milder influenza. LAIV efficacy versus placebo was 95.4% [95% confidence interval: 88.5, 98.1] (year 1) and 88.5% [77.4, 94.9] (year 2) against moderate/severe influenza and 91.4% [77.9, 96.7] (year 1) and 84.2% [56.7, 94.3] (year 2) against milder influenza. The relative efficacy of LAIV versus IIV was 52.2% [31.6, 66.6] for moderate/severe influenza and 45.0% [28.6, 57.5] for milder influenza. Efficacy against all influenza illnesses, regardless of severity, is critical to prevent influenza illness and transmission in the community.</abstract><cop>Kidlington</cop><pub>Elsevier Ltd</pub><pmid>25131746</pmid><doi>10.1016/j.vaccine.2014.07.097</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2014-09, Vol.32 (43), p.5546-5548 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1622609962 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Allergy and Immunology Applied microbiology Biological and medical sciences Child Child, Preschool Disease severity Fundamental and applied biological sciences. Psychology Humans Illnesses Influenza Influenza Vaccines - therapeutic use Influenza, Human - prevention & control Laboratories Live attenuated influenza vaccine Microbiology Randomized Controlled Trials as Topic Respiratory tract Severity of Illness Index Studies Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Vaccines, Attenuated - therapeutic use |
| title | Efficacy of live attenuated influenza vaccine against influenza illness in children as a function of illness severity |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T07%3A16%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20live%20attenuated%20influenza%20vaccine%20against%20influenza%20illness%20in%20children%20as%20a%20function%20of%20illness%20severity&rft.jtitle=Vaccine&rft.au=Ambrose,%20Christopher%20S&rft.date=2014-09-29&rft.volume=32&rft.issue=43&rft.spage=5546&rft.epage=5548&rft.pages=5546-5548&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/j.vaccine.2014.07.097&rft_dat=%3Cproquest_cross%3E3471990361%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1616453216&rft_id=info:pmid/25131746&rft_els_id=1_s2_0_S0264410X14010792&rfr_iscdi=true |